- Home
- WEYS vs ITOS Comparison
WEYS vs ITOS Comparison
Compare WEYS & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEYS
- ITOS
- Stock Information
- Founded
- WEYS 1906
- ITOS 2011
- Country
- WEYS United States
- ITOS United States
- Employees
- WEYS N/A
- ITOS N/A
- Industry
- WEYS Apparel
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WEYS Consumer Staples
- ITOS Health Care
- Exchange
- WEYS Nasdaq
- ITOS Nasdaq
- Market Cap
- WEYS 303.2M
- ITOS 270.7M
- IPO Year
- WEYS N/A
- ITOS 2020
- Fundamental
- Price
- WEYS $33.12
- ITOS $10.09
- Analyst Decision
- WEYS
- ITOS Hold
- Analyst Count
- WEYS 0
- ITOS 6
- Target Price
- WEYS N/A
- ITOS $10.60
- AVG Volume (30 Days)
- WEYS 13.2K
- ITOS 1.7M
- Earning Date
- WEYS 08-05-2025
- ITOS 08-07-2025
- Dividend Yield
- WEYS 3.43%
- ITOS N/A
- EPS Growth
- WEYS N/A
- ITOS N/A
- EPS
- WEYS 3.04
- ITOS N/A
- Revenue
- WEYS $286,762,000.00
- ITOS $35,000,000.00
- Revenue This Year
- WEYS N/A
- ITOS N/A
- Revenue Next Year
- WEYS N/A
- ITOS N/A
- P/E Ratio
- WEYS $10.30
- ITOS N/A
- Revenue Growth
- WEYS N/A
- ITOS 177.89
- 52 Week Low
- WEYS $25.51
- ITOS $4.80
- 52 Week High
- WEYS $41.05
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- WEYS 62.08
- ITOS 66.49
- Support Level
- WEYS $29.72
- ITOS $9.91
- Resistance Level
- WEYS $33.22
- ITOS $10.20
- Average True Range (ATR)
- WEYS 1.10
- ITOS 0.16
- MACD
- WEYS 0.16
- ITOS -0.11
- Stochastic Oscillator
- WEYS 100.00
- ITOS 38.75
About WEYS Weyco Group Inc.
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.